Institutional Biosafety Committee (IBC) FAQ's
Where can I get information on the NIH Guidelines?
The National Institutes of Health Office of Science Policy (NIH OSP) provides an electronic version of the NIH Guidelines here.
What does the IBC do?
The Institutional Biosafety Committee is responsible for the local review and oversight of recombinant or synthetic nucleic acid molecule research subject to the NIH Guidelines and ensures that the research is conducted in compliance with the NIH Guidelines.
What is the IBC meeting frequency?
IBC meetings are scheduled for the 2nd Tuesday of each month and will be held as needed to conduct the IBC's required functions.
When am I required to complete an IBC registration form?
Research requiring IBC registration is outlined on the IBC Protocol Submission webpage. The registration form must be submitted to ibc@kumc.edu.
When will the IBC review my registration form?
Registrations or addendums submitted by the 25th of the month will be reviewed at the following month's IBC meeting. For example, a registration submitted on June 15 will be reviewed at the July meeting.
Can I attend the IBC meeting at which my registration will be reviewed?
Yes. Principal Investigators (PIs) are welcome, and in fact, encouraged to attend to provide a brief overview of their project and resolve any questions or concerns from the committee. This can help expedite the review process.
I am certain that my research is exempt from the NIH Guidelines. Am I exempt from submitting an IBC registration?
No. Completion of an IBC registration form is required to validate if the work is indeed exempt. Specific questions on the registration form and an initial review by the BSO will determine if the work is covered under Section III-F (exempt experiments) or Sections III-A through III-E. If the work is deemed exempt under Section III-F, the registration can be reviewed and approved administratively without going to committee review. If the work falls under Sections III-A through III-E, the registration will undergo full committee review.